Additional file 5: of Serum levels of B-cell activating factor of the TNF family (BAFF) correlate with anti-Jo-1 autoantibodies levels and disease activity in patients with anti-Jo-1positive polymyositis and dermatomyositis

The scatter plots of source data for correlational analysis presented in Table 3. Changes between first two visits (Δ = 1st visit – 2nd visit) of (A) BAFF plotted against Δanti-Jo-1, changes in both BAFF and anti-Jo-1 plotted in columns against parameters of activity in rows. These are: (B) changes in markers of muscle impairment (ΔCK, Δmyoglobin, ΔALT and ΔAST) and (C) changes in clinical disease activity assessments (Δmuscle, Δglobal, Δskeletal within the entire patient group, Δcutaneous within patients with dermatomyositis (DM), and Δpulmonary within patients with lung involvement (ILD)). Statistics are: r = Spearman’s correlation coefficient; p = p value. A single outlying value of Δanti-Jo-1 is highlighted by a red circle. The graphs with exclusion of the outlier are plotted in the right column. The significance of some correlations became even stronger after exclusion of the outlier. (PDF 535 kb

Associations of IL-35 levels in synovial fluid with synovial fluid leukocyte count (a), serum CRP levels (b) and DAS28-ESR (c).

<p>CRP, C-reactive protein; DAS28, 28 joint disease activity score calculated with ESR, erythrocyte sedimentation rate.</p

Additional file 1: of Serum levels of B-cell activating factor of the TNF family (BAFF) correlate with anti-Jo-1 autoantibodies levels and disease activity in patients with anti-Jo-1positive polymyositis and dermatomyositis

Design of data collection. Graphical representation of the time flow of individual patient visits. The blue background highlights cases followed for more than two time points. (PDF 122 kb

Circulating and synovial fluid levels of IL-35 in patients with established and early rheumatoid arthritis and subjects with osteoarthritis.

<p>The introduction of treatment in early RA resulted in significantly decreased levels of IL-35 after 12 weeks of therapy. OA, osteoarthritis; RA, rheumatoid arthritis.</p

Demographic Characteristics of Patients with Treatment Naïve Early and Established Rheumatoid Arthritis and Control Individuals with Osteoarthritis.

<p>Values are the mean ± SD, unless otherwise stated. BMI, body mass index; DAS, disease activity score; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; csDMARDs, conventional synthetic disease modifying antirheumatic drugs; bDMARDs, biologic disease modifying antirheumatic drugs; RFs, rheumatoid factors; anti-CCP, anti-cyclic citrullinated peptide; NA, not applicable. Types of bDMARDs: anti-TNFα (etanercept 3x, adalimumab 2x and golimumab 1x), anti-CD20 (rituximab 2x), anti-IL6R (tocilizumab 2x) and anti-IL17 (secukinumab 1x, open phase clinical trial).</p><p>*p<0.05 for pairwise comparisons with ERA;</p><p>^±p<0.001 for pairwise comparisons with ERA;</p><p>^§p<0.01 for pairwise comparisons with RA;</p><p>^≠p<0.01 for pairwise comparisons with ERA;</p><p>***p<0.001 for pairwise comparisons with ERA wk 0;</p><p>^ǂp<0.001 for pairwise comparisons with ERA and RA</p><p>Demographic Characteristics of Patients with Treatment Naïve Early and Established Rheumatoid Arthritis and Control Individuals with Osteoarthritis.</p

Additional file 3: of Serum levels of B-cell activating factor of the TNF family (BAFF) correlate with anti-Jo-1 autoantibodies levels and disease activity in patients with anti-Jo-1positive polymyositis and dermatomyositis

The scatter plots of source cross-sectional data for correlational analysis presented in Table 2. The values of levels of BAFF, anti-Jo-1 antibodies, and CRP in serum are plotted in columns against the serum levels of markers of muscle impairment (CK, myoglobin, and AST) and CRP in rows. Based on the non-normal distribution, the logarithmically transformed data are plotted. Statistics are: r = Spearman’s correlation coefficient; p = p value. (PDF 540 kb

Additional file 2: of Serum levels of B-cell activating factor of the TNF family (BAFF) correlate with anti-Jo-1 autoantibodies levels and disease activity in patients with anti-Jo-1positive polymyositis and dermatomyositis

The application method of the hierarchical linear model (HLM). Detailed explanation of HLM principles, its use for the unbalanced designs, and interpretation of results. (PDF 199 kb

Association between circulating miRNAs and spinal involvement in patients with axial spondyloarthritis

<div><p>Objectives</p><p>Dysregulation of miRNAs and their target genes contributes to the pathophysiology of autoimmune diseases. Circulating miRNAs may serve as diagnostic/prognostic biomarkers. We aimed to investigate the association between circulating miRNAs, disease activity and spinal involvement in patients with axial spondyloarthritis (AxSpA).</p><p>Methods</p><p>Total RNA was isolated from the plasma of patients with non-radiographic (nr)AxSpA, patients with ankylosing spondylitis (AS) and healthy controls (HC) via phenol-chloroform extraction. A total of 760 miRNAs were analysed with TaqMan^® Low Density Arrays, and the expression of 21 miRNAs was assessed using single assays.</p><p>Results</p><p>Comprehensive analysis demonstrated the differential expression of miRNAs among patients with progressive spinal disease. Of the 21 miRNAs selected according to their expression patterns, the levels of miR-625-3p were significantly different between nr-AxSpA patients and HCs. We found no correlation between miRNA levels and Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) in nr-AxSpA patients. Selected miRNAs, such as miR-29a-3p, miR-146a-5p or miR-222-3p with an established role in extracellular matrix formation and inflammation were associated with spinal changes and/or disease activity assessed by BASDAI in AS patients, including miR-625-3p reflecting disease activity in AS with spinal involvement.</p><p>Conclusions</p><p>Our data indicate that circulating miRNAs play a role in the pathogenesis of AxSpA and are also suggestive of their potential as biomarkers of disease progression. We hypothesize that differential systemic levels of miRNA expression reflect miRNA dysregulation at sites of spinal inflammation or bone formation where these molecules contribute to the development of pathophysiological features typical of AxSpA.</p></div

Additional file 3: of Serum tenascin-C discriminates patients with active SLE from inactive patients and healthy controls and predicts the need to escalate immunosuppressive therapy: a cohort study

a Cross-sectional associations between serum tenascin-C levels and positivity of anti-ds-DNA antibodies at the inception visit (univariate analysis). b Cross-sectional associations between serum tenascin-C levels and positivity of anti-nucleosome antibodies at the inception visit (univariate analysis). (ZIP 46 kb

Differences in the levels of circulating miRNAs between healthy controls, patients with non-radiographic AxSpA (nr-AxSpA) and patients with ankylosing spondylitis (AS) with isolated sacroiliitis and spinal involvement (AS II-V).

<p>Black symbols indicate patients with bamboo spine. *p<0.05, **p<0.01, ***p<0.001.</p